Table of Contents
One of America’s leading Black Executive, Yvonne Greenstreet, the president and CEO of Alnylam Pharmaceuticals, received a total compensation package of $4.58 million from the U.S. biopharmaceutical company in 2022, attributed to her contributions to the organization’s financial success.
Her 2022 compensation package comprises a base salary of $0.85 million and a performance-based short-term incentive of $1.24 million — a direct reflection of her pivotal role in leading the biopharmaceutical group toward impressive financial milestones during the year.
The highly accomplished biotechnology executive also received a long-term incentive award of $2.5 million, reflecting her unwavering dedication and expertise as a seasoned pharmaceutical executive — her leadership not only propels the company forward but also redefines the narrative of innovation within the dynamic biopharmaceutical industry.
Yvonne Greenstreet’s leadership propels Alnylam Pharmaceuticals to achieve $869-million profit in 2022
Thanks to Greenstreet’s strategic leadership, Alnylam Pharmaceuticals has secured its position as one of the world’s leading biopharmaceutical companies, recording a 23.36 percent surge in gross profit—from $704 million in 2021 to $869 million at the end of 2022.
As one of the few Black women at the helm of a pharmaceutical enterprise, Greenstreet’s rise to COO in 2016 marked the beginning of her impactful journey at Alnylam.
Later, she took on the dual roles of CEO and President in late 2021 — a testament to her managerial and leadership skills that played a pivotal role in shaping the company’s narrative and solidifying her position as a top figure in the biopharmaceutical industry.
Yvonne Greenstreet’s stake in Alnylam Pharmaceuticals is worth $26 million
Under her watch and rich leadership — spearheading transformative change for patients worldwide — Greenstreet has led Alnylam to impressive financial milestones — with the company’s revenue growing by 35 percent to $1.04 billion in 2022. However, its assets declined from $3.64 billion in 2021 to $3.55 billion in 2022.
Beyond her executive and governance roles, Greenstreet owns a minority 0.03-percent stake in Alnylam Pharmaceutical — equivalent to 165,090 ordinary shares. This stake presently commands a valuation of $26.64 million, underscoring her vested commitment to the continued triumph of the pharmaceutical giant.
